

Fabrizio Stocchi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5154298/fabrizio-stocchi-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

298
papers

15,437
citations

60
h-index

117
g-index

333
ext. papers

17,723
ext. citations

5.6
avg, IF

6.14
L-index

#	Paper	IF	Citations
298	Safinamide in the treatment pathway of Parkinson's Disease: a European Delphi Consensus.. <i>Npj Parkinson's Disease</i> , 2022 , 8, 17	9.7	0
297	Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases.. <i>Neurobiology of Aging</i> , 2022 , 115, 88-108	5.6	0
296	The Added Benefit of Opicapone When Used Early in Parkinson's Disease Patients With Levodopa-Induced Motor Fluctuations: A Analysis of BIPARK-I and -II. <i>Frontiers in Neurology</i> , 2021 , 12, 754016	4.1	0
295	Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2021 , 93, 27-30	3.6	1
294	An evaluation of the efficacy and value of CVT-301 for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2021 , 22, 965-972	4	
293	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1528-1553	1.2	12
292	Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. <i>Npj Parkinson's Disease</i> , 2021 , 7, 48	9.7	9
291	Effectiveness of an herbaceous derivatives, PHGG, plus sodium hyaluronate in the treatment of chronic constipation in patients with Parkinson's disease: a pilot study. <i>Neurological Sciences</i> , 2021 , 1	3.5	
290	The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease. <i>Drug Design, Development and Therapy</i> , 2021 , 15, 2507-2517	4.4	3
289	Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study. <i>Journal of Parkinson's Disease</i> , 2021 , 11, 177-186	5.3	10
288	Functional motor disorders associated with other neurological diseases: Beyond the boundaries of "organic" neurology. <i>European Journal of Neurology</i> , 2021 , 28, 1752-1758	6	14
287	Abnormalities of Cortical Sources of Resting State Alpha Electroencephalographic Rhythms are Related to Education Attainment in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment. <i>Cerebral Cortex</i> , 2021 , 31, 2220-2237	5.1	3
286	Stacked autoencoders as new models for an accurate Alzheimer's disease classification support using resting-state EEG and MRI measurements. <i>Clinical Neurophysiology</i> , 2021 , 132, 232-245	4.3	14
285	The PRIAMO study: age- and sex-related relationship between prodromal constipation and disease phenotype in early Parkinson's disease. <i>Journal of Neurology</i> , 2021 , 268, 448-454	5.5	11
284	Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study. <i>European Journal of Neurology</i> , 2021 , 28, 349-354	6	8
283	Are there consistent abnormalities in event-related EEG oscillations in patients with Alzheimer's disease compared to other diseases belonging to dementia?. <i>Psychophysiology</i> , 2021 , e13934	4.1	5
282	On-Demand Therapy for OFF Episodes in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 2244-2253	7	3

281	Resting State Alpha Electroencephalographic Rhythms Are Differently Related to Aging in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021 , 82, 1085-1114	4.3	2
280	A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value. <i>Journal of Neurology</i> , 2021 , 1	5.5	1
279	Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson's Disease: A Pooled Analysis of 8 Phase 2b/3 Trials. <i>Journal of Parkinson's Disease</i> , 2021 , 11, 1663-1675	5.3	4
278	Consensus on the treatment of dysphagia in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2021 , 430, 120008	3.2	2
277	Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study. <i>Movement Disorders</i> , 2021 , 36, 2687-2692	7	3
276	Functional gait disorders: Demographic and clinical correlations. <i>Parkinsonism and Related Disorders</i> , 2021 , 91, 32-36	3.6	2
275	Resting State Alpha Electroencephalographic Rhythms Are Affected by Sex in Cognitively Unimpaired Seniors and Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment: A Retrospective and Exploratory Study. <i>Cerebral Cortex</i> , 2021 ,	5.1	2
274	Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to motor visual hallucinations in patients with Parkinson's and Lewy body diseases. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045811	1.2	
273	Sensitivity and specificity of EEG biomarkers of AD at the preclinical stage. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045832	1.2	
272	Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to visual hallucinations in patients with Parkinson's and Lewy body diseases. <i>Alzheimer's and Dementia</i> , 2020 , 16, e045886	1.2	1
271	Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study. <i>Neurobiology of Aging</i> , 2020 , 91, 88-111	5.6	13
270	Does the Degree of Trunk Bending Predict Patient Disability, Motor Impairment, Falls, and Back Pain in Parkinson's Disease?. <i>Frontiers in Neurology</i> , 2020 , 11, 207	4.1	4
269	Effect of family history, occupation and diet on the risk of Parkinson disease: A case-control study. <i>PLoS ONE</i> , 2020 , 15, e0243612	3.7	5
268	A novel summary kinematic index for postural characterization in subjects with Parkinson's disease. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2020 , 56, 142-147	4.4	5
267	Ongoing Electroencephalographic Rhythms Related to Exploratory Movements in Transgenic TASTPM Mice. <i>Journal of Alzheimer's Disease</i> , 2020 , 78, 291-308	4.3	0
266	Extended release levodopa at bedtime as a treatment for nocturia in Parkinson's disease: An open label study. <i>Journal of the Neurological Sciences</i> , 2020 , 410, 116625	3.2	7
265	Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms. <i>Clinical Neurophysiology</i> , 2020 , 131, 2716-2731	4.3	3
264	Resting-state posterior alpha rhythms are abnormal in subjective memory complaint seniors with preclinical Alzheimer's neuropathology and high education level: the INSIGHT-preAD study. <i>Neurobiology of Aging</i> , 2020 , 90, 43-59	5.6	12

263	Abnormalities of Cortical Sources of Resting State Delta Electroencephalographic Rhythms Are Related to Epileptiform Activity in Patients With Amnesic Mild Cognitive Impairment Not Due to Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2020 , 11, 514136	4.1	3
262	The impact of intestinal microbiota on weight loss in Parkinson's disease patients: a pilot study. <i>Future Microbiology</i> , 2020 , 15, 1393-1404	2.9	0
261	Resting-state electroencephalographic delta rhythms may reflect global cortical arousal in healthy old seniors and patients with Alzheimer's disease dementia. <i>International Journal of Psychophysiology</i> , 2020 , 158, 259-270	2.9	4
260	Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 920-929	2.2	20
259	Safety considerations when using non-ergot dopamine agonists to treat Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1155-1172	4.1	1
258	What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. <i>Neurobiology of Aging</i> , 2020 , 85, 58-73	5.6	59
257	Non-motor outcomes depend on location of neurostimulation in Parkinson's disease. <i>Brain</i> , 2019 , 142, 3592-3604	11.2	54
256	Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases. <i>Neurobiology of Aging</i> , 2019 , 77, 112-127	5.6	12
255	Extensive validation study of the Parkinson's Disease Composite Scale. <i>European Journal of Neurology</i> , 2019 , 26, 1281-1288	6	8
254	Football Players Do Not Show "Neural Efficiency" in Cortical Activity Related to Visuospatial Information Processing During Football Scenes: An EEG Mapping Study. <i>Frontiers in Psychology</i> , 2019 , 10, 890	3.4	5
253	Are All Dopamine Agonists Essentially the Same?. <i>Drugs</i> , 2019 , 79, 693-703	12.1	13
252	Clinical and pharmacokinetics equivalence of multiple doses of levodopa benserazide generic formulation vs the originator (Madopar). <i>British Journal of Clinical Pharmacology</i> , 2019 , 85, 2605-2613	3.8	1
251	Postural Abnormalities in Parkinson's Disease: An Epidemiological and Clinical Multicenter Study. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 576-585	2.2	15
250	A systematic review on the clinical experience with melevodopa/carbidopa fixed combination in patients with Parkinson disease. <i>Minerva Medica</i> , 2019 , 110, 575-585	2.2	1
249	Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline dopamine agonist use: Post-hoc analysis from double-blind combined BIPARK-I and II data. <i>Journal of the Neurological Sciences</i> , 2019 , 405, 200-201	3.2	
248	Efficacy of opicapone in Parkinson's disease patients with Early-motor fluctuations: Patient and clinical global impression of change from the BIPARK-I double-blind experience. <i>Journal of the Neurological Sciences</i> , 2019 , 405, 191-192	3.2	
247	Switching from double-blind entacapone or placebo to open-label opicapone: UPDRS-II and III results from patients who ended 1-year BIPARK-I extension on opicapone 50 mg. <i>Journal of the Neurological Sciences</i> , 2019 , 405, 237	3.2	
246	Efficacy of opicapone in Parkinson's disease patients according to baseline pramipexole use: A post-hoc analysis from combined BIPARK-I and II. <i>Journal of the Neurological Sciences</i> , 2019 , 405, 192-193 ²		

245	Validity of the wall goniometer as a screening tool to detect postural abnormalities in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 69, 159-165	3.6	9
244	Applications of the European Parkinson's Disease Association sponsored Parkinson's Disease Composite Scale (PDCS). <i>Npj Parkinson's Disease</i> , 2019 , 5, 26	9.7	4
243	Incidence of treatment-emergent adverse events in Parkinson's disease patients according to baseline disease severity: Post-hoc analysis from double-blind combined BIPARK-I and II data. <i>Journal of the Neurological Sciences</i> , 2019 , 405, 201-202	3.2	
242	Incidence of treatment-emergent adverse events in Parkinson's disease patients according to race: Post-hoc analysis from double-blind combined BIPARK-I and II data. <i>Journal of the Neurological Sciences</i> , 2019 , 405, 202-203	3.2	
241	Levodopa may affect cortical excitability in Parkinson's disease patients with cognitive deficits as revealed by reduced activity of cortical sources of resting state electroencephalographic rhythms. <i>Neurobiology of Aging</i> , 2019 , 73, 9-20	5.6	19
240	Early-morning OFF and levodopa dose failures in patients with Parkinson's disease attending a routine clinical appointment using Time-to-ON Questionnaire. <i>European Journal of Neurology</i> , 2019 , 26, 821-826	6	9
239	Continuous versus intermittent oral administration of levodopa in Parkinson's disease patients with motor fluctuations: A pharmacokinetics, safety, and efficacy study. <i>Movement Disorders</i> , 2019 , 34, 425-429	7.9	6
238	Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body Diseases. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 247-268	4.3	30
237	Levodopa: A new look at an old friend. <i>Movement Disorders</i> , 2018 , 33, 859-866	7	46
236	Functional cortical source connectivity of resting state electroencephalographic alpha rhythms shows similar abnormalities in patients with mild cognitive impairment due to Alzheimer's and Parkinson's diseases. <i>Clinical Neurophysiology</i> , 2018 , 129, 766-782	4.3	30
235	The spectrum of "off" in Parkinson's disease: What have we learned over 40 years?. <i>Parkinsonism and Related Disorders</i> , 2018 , 51, 9-16	3.6	63
234	Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. <i>Neurobiology of Aging</i> , 2018 , 65, 18-40	5.6	30
233	Timed Up and Go evaluation with wearable devices: Validation in Parkinson's disease. <i>Journal of Bodywork and Movement Therapies</i> , 2018 , 22, 390-395	1.6	23
232	Peripheral neurostimulation breaks the shuffling steps patterns in Parkinsonian gait: a double blind randomized longitudinal study with automated mechanical peripheral stimulation. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2018 , 54, 860-865	4.4	2
231	Analyzing gait variability and dual-task interference in patients with Parkinson's disease and freezing by means of the word-color Stroop test. <i>Aging Clinical and Experimental Research</i> , 2018 , 30, 1137-1142	4.8	7
230	The Parkinson's Disease Composite Scale: results of the first validation study. <i>European Journal of Neurology</i> , 2018 , 25, 503-511	6	16
229	Mining clinical and laboratory data of neurodegenerative diseases by Machine Learning: transcriptomic biomarkers 2018 ,		1
228	O1-10-04: ABNORMALITIES OF RESTING STATE FUNCTIONAL CORTICAL CONNECTIVITY IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S AND LEWY BODY DISEASES: AN EEG STUDY 2018 , 14, P244-P245		

227	Pharmacokinetic drug evaluation of CVT-301 for the treatment of Parkinson's disease. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 1189-1195	5.5	15
226	Does fatigue in Parkinson's disease correlate with autonomic nervous system dysfunction?. <i>Neurological Sciences</i> , 2018 , 39, 2169-2174	3.5	5
225	Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. <i>Movement Disorders</i> , 2018 , 33, 1528-1539	7	49
224	Istradefylline for the treatment of Parkinson's disease: is it a promising strategy?. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1821-1828	4	19
223	Mutations in TMEM230 are not a common cause of Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 302-304	7	12
222	Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. <i>Neurobiology of Aging</i> , 2017 , 55, 143-158	5.6	46
221	Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. <i>Neurology</i> , 2017 , 88, 2198-2206	6.5	41
220	Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA. <i>Expert Review of Neurotherapeutics</i> , 2017 , 17, 649-659	4.3	9
219	Abnormalities of Cortical Neural Synchronization Mechanisms in Subjects with Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases: An EEG Study. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 339-358	4.3	26
218	Factors influencing psychological well-being in patients with Parkinson's disease. <i>PLoS ONE</i> , 2017 , 12, e0189682	3.7	20
217	Constipation in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017 , 134, 811-826	4.4	38
216	Non motor symptoms in progressive supranuclear palsy: prevalence and severity. <i>Npj Parkinson's Disease</i> , 2017 , 3, 35	9.7	15
215	The coefficient of friction in Parkinson's disease gait. <i>Functional Neurology</i> , 2017 , 32, 17-22	2.2	3
214	Advances in dopamine receptor agonists for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 1889-902	4	26
213	Use of the gait profile score for the quantification of the effects of robot-assisted gait training in patients with Parkinson's disease 2016 ,		1
212	Long-term effects of rasagiline and the natural history of treated Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1489-1496	7	35
211	A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1356-65	7	61
210	Classification of Healthy Subjects and Alzheimer's Disease Patients with Dementia from Cortical Sources of Resting State EEG Rhythms: A Study Using Artificial Neural Networks. <i>Frontiers in Neuroscience</i> , 2016 , 10, 604	5.1	35

209	Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide. <i>Drug Design, Development and Therapy</i> , 2016 , 10, 609-18	4.4	32
208	Robot-assisted gait training versus treadmill training in patients with Parkinson's disease: a kinematic evaluation with gait profile score. <i>Functional Neurology</i> , 2016 , 31, 163-70	2.2	24
207	A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. <i>Movement Disorders</i> , 2016 , 31, 1049-54	7	24
206	Mavoglurant in Parkinson's patients with L-Dopa-induced dyskinesias: Two randomized phase 2 studies. <i>Movement Disorders</i> , 2016 , 31, 1054-8	7	45
205	Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. <i>Journal of Neural Transmission</i> , 2015 , 122, 799-808	4.3	6
204	Neuroprotection in Parkinson's disease: a difficult challenge. <i>Lancet Neurology</i> , 2015 , 14, 780-781	24.1	2
203	Prevalence and associated features of self-reported freezing of gait in Parkinson disease: The DEEP FOG study. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 644-9	3.6	58
202	The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 287-91	3.6	72
201	Rasagiline for the treatment of Parkinson's disease: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2231-41	4	25
200	Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned. <i>JAMA Neurology</i> , 2015 , 72, 1491-500	17.2	62
199	Move for Change Part III: a European survey evaluating the impact of the EPDA Charter for People with Parkinson's Disease. <i>European Journal of Neurology</i> , 2015 , 22, 133-41, e8-9	6	15
198	How to optimize the treatment of early stage Parkinson's disease. <i>Translational Neurodegeneration</i> , 2015 , 4, 4	10.3	19
197	The Parkinsonian Gait Spatiotemporal Parameters Quantified by a Single Inertial Sensor before and after Automated Mechanical Peripheral Stimulation Treatment. <i>Parkinson's Disease</i> , 2015 , 2015, 390512	2.6	30
196	L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study. <i>Parkinson's Disease</i> , 2015 , 2015, 369465	2.6	7
195	The "gender factor" in wearing-off among patients with Parkinson's disease: a post hoc analysis of DEEP study. <i>Scientific World Journal</i> , 2015 , 2015, 787451	2.2	38
194	Long-term effects of automated mechanical peripheral stimulation on gait patterns of patients with Parkinson's disease. <i>International Journal of Rehabilitation Research</i> , 2015 , 38, 238-45	1.8	16
193	Acute Modulation of Brain Connectivity in Parkinson Disease after Automatic Mechanical Peripheral Stimulation: A Pilot Study. <i>PLoS ONE</i> , 2015 , 10, e0137977	3.7	19
192	The Lee Silverman Voice Treatment (LSVT [®]) speech therapy in progressive supranuclear palsy. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2015 , 51, 569-74	4.4	14

191	Drug safety evaluation of ropinirole prolonged release. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 383-9	4.1	9
190	Therapy for Parkinson's disease: what is in the pipeline?. <i>Neurotherapeutics</i> , 2014 , 11, 24-33	6.4	18
189	Early DEtection of wEaring off in Parkinson disease: the DEEP study. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 204-11	3.6	90
188	Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 1273-80	7	152
187	Characterizing motor and non-motor aspects of early-morning off periods in Parkinson's disease: an international multicenter study. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1231-5	3.6	46
186	Initiating levodopa therapy for Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 430	7	5
185	The relevance of dopaminergic level in nocturnal disability in Parkinson's disease: implications of continuous dopaminergic stimulation at night to treat the symptoms. <i>Journal of Neural Transmission</i> , 2014 , 121 Suppl 1, S79-83	4.3	15
184	Prevalence of fatigue in Parkinson disease and its clinical correlates. <i>Neurology</i> , 2014 , 83, 215-20	6.5	76
183	Effects of robot assisted gait training in progressive supranuclear palsy (PSP): a preliminary report. <i>Frontiers in Human Neuroscience</i> , 2014 , 8, 207	3.3	14
182	Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 1335-40	3.6	55
181	Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. <i>Movement Disorders</i> , 2014 , 29, 229-37	7	173
180	Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease. <i>European Journal of Neurology</i> , 2014 , 21, 357-60	6	29
179	A systems medicine clinical platform for understanding and managing non- communicable diseases. <i>Current Pharmaceutical Design</i> , 2014 , 20, 5945-56	3.3	23
178	Robot-assisted walking training for individuals with Parkinson's disease: a pilot randomized controlled trial. <i>BMC Neurology</i> , 2013 , 13, 50	3.1	42
177	Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. <i>Journal of Neurology</i> , 2013 , 260, 1731-42	5.5	20
176	Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 1064-71	7	283
175	Obstacles to the development of a neuroprotective therapy for Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 3-7	7	33
174	AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. <i>Movement Disorders</i> , 2013 , 28, 1838-46	7	107

173	Move for Change Part II: a European survey evaluating the impact of the EPDA Charter for people with Parkinson's disease. <i>European Journal of Neurology</i> , 2013 , 20, 461-472	6	16
172	Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. <i>European Journal of Neurology</i> , 2013 , 20, 271-80	6	67
171	The vatican meeting on neuroprotection for Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 1-2	7	2
170	A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: meeting an unmet need. <i>PLoS ONE</i> , 2013 , 8, e57221	3.7	73
169	The relation between Parkinson's disease and ageing. Comparison of the gait patterns of young Parkinson's disease subjects with healthy elderly subjects. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2013 , 49, 161-7	4.4	10
168	Move for change part I: a European survey evaluating the impact of the EPDA Charter for People with Parkinson's disease. <i>European Journal of Neurology</i> , 2012 , 19, 402-10	6	36
167	A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. <i>Movement Disorders</i> , 2012 , 27, 106-12	7	87
166	Linguistic, psychometric validation and diagnostic ability assessment of an Italian version of a 19-item wearing-off questionnaire for wearing-off detection in Parkinson's disease. <i>Neurological Sciences</i> , 2012 , 33, 1319-27	3.5	21
165	A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2269-80	4	19
164	Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders. <i>Neurological Sciences</i> , 2012 , 33, 585-93	3.5	15
163	Observational study of sleep-related disorders in Italian patients with Parkinson's disease: usefulness of the Italian version of Parkinson's disease sleep scale. <i>Neurological Sciences</i> , 2012 , 33, 689-94	3.5	16
162	Non-Dopaminergic Approaches to the Treatment of Parkinson's Disease 2011 , 432-454		
161	Overview of the Medical Treatment of the Non-Motor and Non-Dopaminergic Features of Parkinson's Disease 2011 , 394-408		
160	The possible clinical predictors of fatigue in Parkinson's disease: a study of 135 patients as part of international nonmotor scale validation project. <i>Parkinson's Disease</i> , 2011 , 2011, 125271	2.6	11
159	Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. <i>European Journal of Neurology</i> , 2011 , 18, 1373-8	6	27
158	A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. <i>Lancet Neurology</i> , 2011 , 10, 415-23	24.1	159
157	Pain and Paresthesia in Parkinson's Disease 2011 , 315-332		2
156	Continuous dopaminergic stimulation and novel formulations of dopamine agonists. <i>Journal of Neurology</i> , 2011 , 258, S316-22	5.5	60

155	PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 1259-65	7	54
154	Wearing-off scales in Parkinson's disease: critique and recommendations. <i>Movement Disorders</i> , 2011 , 26, 2169-75	7	68
153	Temporal stability of the Unified Dyskinesia Rating Scale. <i>Movement Disorders</i> , 2011 , 26, 2556-9	7	15
152	When do levodopa motor fluctuations first appear in Parkinson's disease?. <i>European Neurology</i> , 2010 , 63, 257-66	2.1	67
151	The concept of continuous dopaminergic stimulation: what we should consider when starting Parkinson's disease treatment. <i>Neurodegenerative Diseases</i> , 2010 , 7, 213-5	2.3	14
150	Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio). <i>Clinical Neuropharmacology</i> , 2010 , 33, 198-203	1.4	10
149	Clinical experiences with levodopa methylester (melevodopa) in patients with Parkinson disease experiencing motor fluctuations: an open-label observational study. <i>Clinical Neuropharmacology</i> , 2010 , 33, 61-6	1.4	12
148	Non-motor symptoms in atypical and secondary parkinsonism: the PRIAMO study. <i>Journal of Neurology</i> , 2010 , 257, 5-14	5.5	115
147	mGLU3 metabotropic glutamate receptors modulate the differentiation of SVZ-derived neural stem cells towards the astrocytic lineage. <i>Glia</i> , 2010 , 58, 813-22	9	21
146	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. <i>Annals of Neurology</i> , 2010 , 68, 18-27	9.4	270
145	The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: an international study using the nonmotor symptoms questionnaire. <i>Movement Disorders</i> , 2010 , 25, 704-9	7	266
144	Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. <i>Movement Disorders</i> , 2010 , 25, 896-905	7	52
143	Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 1881-7	7	17
142	Validation of the freezing of gait questionnaire in patients with Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 655-61	7	245
141	Adherence to antiparkinson medication in a multicenter European study. <i>Movement Disorders</i> , 2009 , 24, 826-32	7	131
140	The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. <i>Movement Disorders</i> , 2009 , 24, 1641-9	7	919
139	A double-blind, delayed-start trial of rasagiline in Parkinson's disease. <i>New England Journal of Medicine</i> , 2009 , 361, 1268-78	59.2	694
138	GIGYF2 mutations are not a frequent cause of familial Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009 , 15, 703-5	3.6	19

137	Peripheral blood mononuclear cells from mild cognitive impairment patients show deregulation of Bax and Sod1 mRNAs. <i>Neuroscience Letters</i> , 2009 , 453, 36-40	3.3	17
136	The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009 , 15 Suppl 1, S9-S15	3.6	29
135	The therapeutic concept of continuous dopaminergic stimulation (CDS) in the treatment of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009 , 15 Suppl 3, S68-71	3.6	29
134	Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. <i>Parkinsonism and Related Disorders</i> , 2009 , 15 Suppl 3, S233-6	3.6	41
133	Dopamine receptor agonists in the treatment of advanced Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009 , 15 Suppl 4, S54-7	3.6	12
132	Metabotropic glutamate receptors regulate differentiation of embryonic stem cells into GABAergic neurons. <i>Cell Death and Differentiation</i> , 2008 , 15, 700-7	12.7	15
131	Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. <i>Current Medical Research and Opinion</i> , 2008 , 24, 2883-95	2.5	87
130	Use of apomorphine in Parkinson's disease. <i>Neurological Sciences</i> , 2008 , 29 Suppl 5, S383-6	3.5	21
129	Treatment of levodopa-induced motor complications. <i>Movement Disorders</i> , 2008 , 23 Suppl 3, S599-612	7	84
128	A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. <i>Movement Disorders</i> , 2008 , 23, 2194-201	7	138
127	Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. <i>Movement Disorders</i> , 2007 , 22, 1623-9	7	375
126	The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. <i>Movement Disorders</i> , 2007 , 22, 1901-11	7	638
125	ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. <i>Neurology</i> , 2007 , 68, 1557-62	6.5	270
124	Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. <i>Clinical Neuropharmacology</i> , 2007 , 30, 18-24	1.4	29
123	Neuroprotection in Parkinson's disease: clinical trials. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2007 , 84, 17-29	3	2
122	Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. <i>Neurology</i> , 2007 , 68, 1108-15	6.5	246
121	Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. <i>Lancet Neurology, The</i> , 2006 , 5, 677-87	24.1	396
120	International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. <i>Movement Disorders</i> , 2006 , 21, 916-23	7	663

119	Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease. <i>Nature Clinical Practice Neurology</i> , 2006 , 2, 382-92		98
118	I.P2 Prevalence of non motor symptoms in Parkinson's Disease: An international survey using NMSQuest in 525 patients. <i>Parkinsonism and Related Disorders</i> , 2006 , 12, 21	3.6	2
117	The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1399-407	4	60
116	Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment. <i>Clinical Neuropharmacology</i> , 2006 , 29, 220-9	1.4	19
115	End-of-dose wearing off in Parkinson disease: a 9-question survey assessment. <i>Clinical Neuropharmacology</i> , 2006 , 29, 312-21	1.4	54
114	Bilateral Implantation of Centromedian-Parafascicularis Complex and GPI: A New Combination of Unconventional Targets for Deep Brain Stimulation in Severe Parkinson Disease. <i>Neuromodulation</i> , 2006 , 9, 221-8	3.1	44
113	Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. <i>International Journal of Clinical Practice</i> , 2006 , 60, 215-21	2.9	8
112	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. <i>European Journal of Human Genetics</i> , 2006 , 14, 322-31	5.3	134
111	End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease. <i>Journal of Neurology</i> , 2006 , 253, 1633-9	5.5	20
110	Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. <i>Neurology</i> , 2006 , 67, S24-9	6.5	53
109	Utility of tolcapone in fluctuating Parkinson's disease. <i>Clinical Interventions in Aging</i> , 2006 , 1, 317-25	4	8
108	A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. <i>Lancet, The</i> , 2005 , 365, 412-5	40	367
107	Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. <i>Lancet, The</i> , 2005 , 365, 947-54	40	486
106	Pathological gambling in Parkinson's disease. <i>Lancet Neurology, The</i> , 2005 , 4, 590-2	24.1	21
105	Case-control study of multiple system atrophy. <i>Movement Disorders</i> , 2005 , 20, 158-63	7	51
104	Novel parkin mutations detected in patients with early-onset Parkinson's disease. <i>Movement Disorders</i> , 2005 , 20, 424-431	7	51
103	Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment. <i>Movement Disorders</i> , 2005 , 20, 726-33	7	186
102	Optimising levodopa therapy for the management of Parkinson's disease. <i>Journal of Neurology</i> , 2005 , 252 Suppl 4, IV43-IV48	5.5	21

101	The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. <i>Journal of Medical Genetics</i> , 2005 , 42, e65	5.8	141
100	Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. <i>Archives of Neurology</i> , 2005 , 62, 905-10		174
99	Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. <i>Neurology</i> , 2005 , 65, 87-95	6.5	276
98	A frequent gene mutation associated with autosomal dominant Parkinson's disease. <i>Lancet, The</i> , 2005 , 365, 412-415	40	339
97	Improvement of motor function in early Parkinson disease by safinamide. <i>Neurology</i> , 2004 , 63, 746-8	6.5	85
96	Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients. <i>Journal of Neural Transmission</i> , 2004 , 111, 173-80	4.3	16
95	Levodopa in the treatment of Parkinson's disease: current controversies. <i>Movement Disorders</i> , 2004 , 19, 997-1005	7	291
94	Continuous apomorphine infusion (CAI) and neuropsychiatric disorders in patients with advanced Parkinson's disease: a follow-up of two years. <i>Archives of Gerontology and Geriatrics</i> , 2004 , 291-6	4	42
93	Variation in the dopaminergic response during the day in Parkinson disease. <i>Clinical Neuropharmacology</i> , 2004 , 27, 116-8	1.4	12
92	Continuous dopaminergic stimulation in early and advanced Parkinson's disease. <i>Neurology</i> , 2004 , 62, S56-63	6.5	62
91	COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?. <i>Neurology</i> , 2004 , 62, S72-81	6.5	60
90	Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease. <i>Clinical Neuropharmacology</i> , 2003 , 26, 151-5	1.4	9
89	Dual dopamine agonist treatment in Parkinson's disease. <i>Journal of Neurology</i> , 2003 , 250, 822-6	5.5	30
88	Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. <i>Neurological Sciences</i> , 2003 , 24, 174-5	3.5	29
87	Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor. <i>Neurological Sciences</i> , 2003 , 24, 217-8	3.5	33
86	HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson's disease. <i>Movement Disorders</i> , 2003 , 18, 337-340	7	27
85	Neuroprotection in Parkinson's disease: clinical trials. <i>Annals of Neurology</i> , 2003 , 53 Suppl 3, S87-97; discussion S97-9	9.4	71
84	Prevention and treatment of motor fluctuations. <i>Parkinsonism and Related Disorders</i> , 2003 , 9 Suppl 2, S73-81	3.6	34

83	Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 250-8	4.6	81
82	Are there clinically significant differences between dopamine agonists. <i>Advances in Neurology</i> , 2003 , 91, 259-66		2
81	Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7. <i>Neurological Sciences</i> , 2002 , 23 Suppl 2, S59-60	3.5	32
80	Modification of respiratory function parameters in patients with severe Parkinson's disease. <i>Neurological Sciences</i> , 2002 , 23 Suppl 2, S69-70	3.5	46
79	Combination of two different dopamine agonists in the management of Parkinson's disease. <i>Neurological Sciences</i> , 2002 , 23 Suppl 2, S115-6	3.5	
78	A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. <i>Journal of Neural Transmission</i> , 2002 , 109, 489-502	4.3	42
77	Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. <i>Brain</i> , 2002 , 125, 2058-66	11.2	109
76	Managing the critical problems of advanced Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2002 , 2, 835-47	4.3	1
75	Problems of Long-Term Levodopa Treatment. <i>Advances in Behavioral Biology</i> , 2002 , 397-402		
74	Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. <i>Neurological Sciences</i> , 2001 , 22, 93-4	3.5	73
73	Epidemiology of multiple system atrophy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. <i>Neurological Sciences</i> , 2001 , 22, 97-9	3.5	43
72	Epidemiology of progressive supranuclear palsy. ESGAP Consortium. European Study Group on Atypical Parkinsonisms. <i>Neurological Sciences</i> , 2001 , 22, 101-3	3.5	21
71	Long-duration effect and the postsynaptic compartment: study using a dopamine agonist with a short half-life. <i>Movement Disorders</i> , 2001 , 16, 301-5	7	28
70	Sleep disorders in Parkinson's disease. <i>Advances in Neurology</i> , 2001 , 86, 289-93		8
69	Anorectal function in multiple system atrophy and Parkinson's disease. <i>Movement Disorders</i> , 2000 , 15, 71-6	7	81
68	Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. <i>Neurology</i> , 2000 , 54, 114-9	6.5	66
67	Continuous dopamine-receptor stimulation in advanced Parkinson's disease. <i>Trends in Neurosciences</i> , 2000 , 23, S109-15	13.3	123
66	A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. <i>Neurology</i> , 1999 , 53, 1415-21	6.5	100

65	The effect of steady-state ropinirole on plasma concentrations of digoxin in patients with Parkinson's disease. <i>British Journal of Clinical Pharmacology</i> , 1999 , 47, 219-22	3.8	13
64	Implantable venous access system for apomorphine infusion in complicated Parkinson's disease. <i>Movement Disorders</i> , 1999 , 14, 358	7	4
63	The tau gene in progressive supranuclear palsy: exclusion of mutations in coding exons and exon 10 splice sites, and identification of a new intronic variant of the disease-associated H1 haplotype in Italian cases. <i>Neuroscience Letters</i> , 1999 , 274, 61-5	3.3	24
62	Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. <i>Movement Disorders</i> , 1998 , 13, 39-45	7	234
61	Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. <i>Movement Disorders</i> , 1998 , 13, 46-51	7	115
60	Sleep disorders in Parkinson's disease. <i>Journal of Neurology</i> , 1998 , 245 Suppl 1, S15-8	5.5	89
59	Co-administration of ropinirole and domperidone during rapid dose escalation of the dopamine agonist. <i>Parkinsonism and Related Disorders</i> , 1998 , 4, 183-8	3.6	7
58	Dopamine Agonists in Parkinson's Disease. <i>CNS Drugs</i> , 1998 , 10, 159-170	6.7	9
57	Direct genetic evidence for involvement of tau in progressive supranuclear palsy. European Study Group on Atypical Parkinsonism Consortium. <i>Neurology</i> , 1998 , 51, 982-5	6.5	76
56	Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1997 , 62, 507-11	5.5	125
55	Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias. <i>Clinical Neuropharmacology</i> , 1997 , 20, 95-115	1.4	61
54	Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. <i>Clinical Neuropharmacology</i> , 1997 , 20, 204-9	1.4	40
53	The long-duration action of levodopa may be due to a postsynaptic effect. <i>Clinical Neuropharmacology</i> , 1997 , 20, 394-401	1.4	38
52	An acute and long-term study with a dispersible formulation of levodopa/benserazide (Madopar®) in Parkinson's disease. <i>European Journal of Neurology</i> , 1997 , 4, 485-490	6	2
51	Determination of apomorphine in human plasma by alumina extraction and high-performance liquid chromatography with electrochemical detection. <i>Forensic Science International</i> , 1997 , 89, 81-91	2.6	15
50	A pharmacological study of cocaine activity in planaria. <i>Comparative Biochemistry and Physiology C, Comparative Pharmacology and Toxicology</i> , 1996 , 115, 41-5		58
49	Motor fluctuations in levodopa treatment: clinical pharmacology. <i>European Neurology</i> , 1996 , 36 Suppl 1, 38-42	2.1	17
48	QT interval and QT dispersion in multiple system atrophy (Shy-Drager syndrome). <i>Clinical Autonomic Research</i> , 1996 , 6, 67-70	4.3	3

47	Transient atrial fibrillation after subcutaneous apomorphine bolus. <i>Movement Disorders</i> , 1996 , 11, 584-57		21
46	Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester. <i>Journal of Neurology</i> , 1996 , 243, 377-80	5.5	20
45	Instrumental diagnosis of multiple system atrophy. <i>Advances in Neurology</i> , 1996 , 69, 421-4		7
44	Ambulatory blood pressure monitoring and cardiovascular function tests in multiple system atrophy. <i>Fundamental and Clinical Pharmacology</i> , 1995 , 9, 187-96	3.1	14
43	The Bereitschaftspotential preceding stepping in patients with isolated gait ignition failure. <i>Movement Disorders</i> , 1995 , 10, 18-21	7	29
42	Analysis of repetitive and nonrepetitive sequential arm movements in patients with Parkinson's disease. <i>Movement Disorders</i> , 1994 , 9, 311-4	7	41
41	Comparison between a fast and a slow release preparation of levodopa and a combination of the two: a clinical and pharmacokinetic study. <i>Clinical Neuropharmacology</i> , 1994 , 17, 38-44	1.4	37
40	Clinical Efficacy of Single Morning Doses of Different Levodopa Formulations. <i>Clinical Neuropharmacology</i> , 1994 , 17, S16-S20	1.4	8
39	The clinical efficacy of a single afternoon dose of levodopa methyl ester: a double-blind cross-over study versus placebo. <i>Functional Neurology</i> , 1994 , 9, 259-64	2.2	14
38	The Bereitschaftspotential preceding simple foot movement and initiation of gait in Parkinson's disease. <i>Neurology</i> , 1993 , 43, 1784-8	6.5	52
37	Morbo di Parkinson: Aspetti fisiopatologici e clinici. <i>The Neuroradiology Journal</i> , 1993 , 6, 99-103		2
36	Botulinum toxin treatment in patients with focal dystonia and hemifacial spasm. A multicenter study of the Italian Movement Disorder Group. <i>Italian Journal of Neurological Sciences</i> , 1993 , 14, 361-7		35
35	Transient left bundle branch block following intravenous lisuride bolus. <i>Fundamental and Clinical Pharmacology</i> , 1993 , 7, 115-7	3.1	1
34	Urodynamic study in the differential diagnosis between multiple system atrophy and Parkinson's disease. <i>Advances in Neurology</i> , 1993 , 60, 434-7		6
33	Apomorphine and lisuride infusion. A comparative chronic study. <i>Advances in Neurology</i> , 1993 , 60, 653-5		20
32	TRH test and the continuous dopaminergic stimulation in complicated Parkinson's disease. <i>European Neurology</i> , 1992 , 32, 65-9	2.1	7
31	The clinical efficacy of single morning doses of levodopa methyl ester: dispersible Madopar and Sinemet plus in Parkinson disease. <i>Clinical Neuropharmacology</i> , 1992 , 15, 501-4	1.4	26
30	Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease. <i>Movement Disorders</i> , 1992 , 7, 249-56	7	18

29	The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease. <i>Clinical Neuropharmacology</i> , 1991 , 14, 241-4	1.4	17
28	Antagonist effect of terguride in Parkinson's disease. <i>Clinical Neuropharmacology</i> , 1991 , 14, 450-6	1.4	7
27	Botulinum A toxin injection in patients with blepharospasm, torticollis and hemifacial spasm. <i>Italian Journal of Neurological Sciences</i> , 1990 , 11, 589-93		10
26	Simultaneous measurement of L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients by improved sample pretreatment and high-performance liquid chromatographic determination. <i>Journal of Chromatography A</i> , 1990 , 511, 167-76	4.5	17
25	Transient cardiac arrest during continuous intravenous infusion of apomorphine. <i>Lancet, The</i> , 1990 , 336, 1321	40	10
24	Levodopa and lisuride intravenous infusions in fluctuating Parkinsonian patients: clinical differences 1990 , 151-160		
23	One year treatment with lisuride delivery pump in Parkinson's disease. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1989 , 13, 173-83	5.5	5
22	Side-effects of subcutaneous apomorphine in Parkinson's disease. <i>Lancet, The</i> , 1989 , 1, 566	40	20
21	Jejunal delivery of levodopa methyl ester. <i>Lancet, The</i> , 1989 , 2, 45-6	40	13
20	A pharmacological study of dopaminergic receptors in planaria. <i>Neuropharmacology</i> , 1989 , 28, 1377-82	5.5	63
19	Effects of terguride in patients with Huntington's disease. <i>Clinical Neuropharmacology</i> , 1989 , 12, 435-9	1.4	7
18	Cardiovascular effects of lisuride continuous intravenous infusion in fluctuating Parkinson's disease. <i>Clinical Neuropharmacology</i> , 1989 , 12, 331-8	1.4	11
17	Correlation between facial involuntary movements and abnormalities of blink and corneal reflexes in Huntington's chorea. <i>Movement Disorders</i> , 1988 , 3, 281-9	7	36
16	Comparison between L-dopa and lisuride intravenous infusions: a clinical study. <i>Movement Disorders</i> , 1988 , 3, 313-9	7	13
15	Improved high-performance liquid chromatographic analysis with double detection system for L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients under L-dopa therapy. <i>Journal of Chromatography A</i> , 1988 , 459, 341-9	4.5	12
14	Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration. <i>Journal of Neural Transmission Supplementum</i> , 1988 , 27, 27-33		6
13	Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease. <i>European Neurology</i> , 1987 , 27 Suppl 1, 54-8	2.1	18
12	Unusual cardiovascular response to intravenous lisuride bolus. Possible drug-induced coronary angiospasm. <i>Chest</i> , 1987 , 91, 792-3	5.3	3

11	Corneal and blink reflexes in Parkinson's disease with "on-off" fluctuations. <i>Movement Disorders</i> , 1987 , 2, 227-35	7	44
10	Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data. <i>Clinical Neuropharmacology</i> , 1986 , 9, 165-81	1.4	38
9	Multicenter trial of L-Deprenyl in Parkinson disease. <i>Italian Journal of Neurological Sciences</i> , 1986 , 7, 133-7		7
8	LISURIDE INFUSION PUMP FOR PARKINSON'S DISEASE. <i>Lancet, The</i> , 1986 , 328, 348-349	40	11
7	Assessment of Non-Motor Features of Parkinson's Disease: Scales and Rating Tools111-125		
6	Bladder Dysfunction in Parkinson's Disease and Other Parkinsonism274-283		0
5	Prospects for Neuroprotective Therapies that can Modulate Non-Dopaminergic Features in Parkinson's Disease455-461		
4	Functional Organization of the Basal Ganglia: Dopaminergic and Non-Dopaminergic Features56-69		
3	Animal Models of Parkinson's Disease: The Non-Motor and Non-Dopaminergic Features79-92		
2	Clinical Trial Measures of the Non-Motor Features of Parkinson's Disease126-133		
1	The Dopaminergic and Non-Dopaminergic Features of Parkinson's Disease1-6		1